The impact of pre-existing autoimmune diseases in myelodysplastic syndrome patients undergoing allogeneic hematopoietic stem cell transplantation: A retrospective cohort study.
Myelodysplastic syndrome (MDS) is frequently accompanied by autoimmune diseases (AD), yet their combined impact on allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains controversial.
APA
Wu N, Liu J, et al. (2026). The impact of pre-existing autoimmune diseases in myelodysplastic syndrome patients undergoing allogeneic hematopoietic stem cell transplantation: A retrospective cohort study.. Clinical immunology (Orlando, Fla.), 110710. https://doi.org/10.1016/j.clim.2026.110710
MLA
Wu N, et al.. "The impact of pre-existing autoimmune diseases in myelodysplastic syndrome patients undergoing allogeneic hematopoietic stem cell transplantation: A retrospective cohort study.." Clinical immunology (Orlando, Fla.), 2026, pp. 110710.
PMID
42044707
Abstract
Myelodysplastic syndrome (MDS) is frequently accompanied by autoimmune diseases (AD), yet their combined impact on allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains controversial. We retrospectively studied 161 MDS patients undergoing allo-HSCT from 2013 to 2024, including 39 with pre-existing AD and 122 matched controls. Patients with AD had significantly lower platelet engraftment, higher relapse rate, inferior leukemia-free survival (LFS) and GVHD-free, relapse-free survival (GRFS). No significant differences were observed in overall survival, acute or chronic GVHD. Subgroup analysis revealed that active AD at transplantation conferred higher relapse and worse GRFS. Pre-existing AD is an independent risk factor for poor outcomes, supporting personalized strategies for this high-risk population.
같은 제1저자의 인용 많은 논문 (5)
- Bridging With Chimeric Antigen Receptor T-Cell Therapy or Chemotherapy to Allo-HSCT in B-ALL: A Comparison of Treatment Complications and Survival.
- AGR2 promotes tumor progression by regulating macrophage polarization via the CD98hc-xCT/p-ERK pathway.
- Gene expression profile, and role of baicalein in the inhibition of thyroid cancer.
- Donor age ≥50 years combined with donor-CI ≥3 identifies a high-risk cohort for adverse outcomes after allogeneic hematopoietic stem cell transplantation in B-cell acute lymphoblastic leukemia.
- High-affinity poly-cytosine DNA modulated metal-organic framework-DNA interactions and their application in detection of hepatocellular carcinoma biomarker.